Skip to main content

Table 3 Stepwise regression analysis for pre-existing diabetic dialysis patients with 5-year survival rate, n = 2956

From: Effect of anti-diabetic drugs in dialysis patients with diabetes: a nationwide retrospective cohort study

Variables Univariate Multivariate
HR (95% CI) P-value aHR (95% CI) P-value
Age > 60 year 2.31 (2.01–2.65)  < 0.001 2.05 (1.78–2.35)  < 0.001
Gender—male 1.09 (0.96–1.24) 0.183   
Anti-diabetic drug use
 Non-user 1   1  
 OHA 0.44 (0.37–0.53)  < 0.001 0.56 (0.49–0.68)  < 0.001
 Insulin 0.52 (0.43–0.63)  < 0.001 0.66 (0.55–0.80)  < 0.001
Region
 Northern 1    
 Central 1.01 (0.86–1.19) 0.900   
 Southern/Eastern 0.94 (0.81–1.09) 0.398   
Insured premium (NT$)
 < 15,840 1    
 15,840–25,000 0.87 (0.75–1.02) 0.084   
 > 25,000 0.80 (0.68–0.95) 0.012   
Urbanization
 Urban 1    
 Sub-urban 1.09 (0.95–1.25) 0.236   
 Rural 1.10 (0.90–1.33) 0.365   
Hospital characteristics
 Medical center 1.03 (0.89–1.19) 0.674   
 Region/others 1    
Number of admissions during the 12 months leading up to dialysis
 0–1 1   1  
 > 1 1.72 (1.51–1.95)  < 0.001 1.59 (1.38–1.83)  < 0.001
Dialysis modality
 Peritoneal dialysis 1    
 Hemodialysis 0.86 (0.64–1.15) 0.306   
Comorbidity
 Hypertension 1.14 (0.98–1.31) 0.070 0.73 (0.67–0.91) 0.002
 Hyperlipidemia 0.80 (0.69–0.93) 0.003   
 Gout 1.07 (0.86–1.32) 0.562   
 Congestive heart failure 1.22 (1.07–1.39) 0.003   
 Cerebrovascular accident 1.35 (1.16–1.57)  < 0.001 1.21 (1.03–1.41) 0.020
 COPD 1.57 (1.27–1.64)  < 0.001 1.21 (0.98–1.49) 0.087
 Chronic liver disease 1.65 (1.32–2.07)  < 0.001 1.48 (1.18–1.86) 0.001
 Malignancy 1.65 (1.36–2.01)  < 0.001 1.24 (1.01–1.52) 0.037
ACEI/ARB use 0.59 (0.52–0.67)  < 0.001 0.56 (0.47–0.68)  < 0.001
Lipid-lowering drug use 0.50 (0.43–0.58)  < 0.001 0.66 (0.55–0.80)  < 0.001
  1. HR hazard ratio, CI confidence interval, aHR adjusted hazard ratio, OHA oral hypoglycemia agents, COPD chronic obstructive pulmonary disease, ACEI angiotensin converting enzyme inhibitors, ARB angiotensin II receptor blockers